Buparlisib (BKM120)

Name: Buparlisib (BKM120)
Brand: Selleck Chemicals
SKU: S2247
Rating: 5 (178 reviews)

For research use only.

Catalog No.S2247 Synonyms: NVP-BKM120

178 publications

CAS No. 944396-07-0

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.

Selleck's Buparlisib (BKM120) has been cited by 178 publications

Cell, 2020, 25;181(7):1596-1611.e27.

PubMed: 32559461 ( click the link to review the publication )

Cancer Cell, 2020, 37(2):183-199

PubMed: 31978326 ( click the link to review the publication )

Nat Immunol, 2020, 21(4):442-454

PubMed: 32152508 ( click the link to review the publication )

Science, 2019, 364(6441)

PubMed: 31097636 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):922-938

PubMed: 30537514 ( click the link to review the publication )

Cancer Cell, 2018, 33(1):91-107

PubMed: 29316436 ( click the link to review the publication )

Cell, 2017, 161(4):803-16

PubMed: 25913192 ( click the link to review the publication )

Cancer Discov, 2017, 7(9):1018-1029

PubMed: 28619981 ( click the link to review the publication )

Nature, 2016, 529(7586):413-417

PubMed: 26735014 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Cancer Discov, 2013, 4(2):232-45

PubMed: 24356096 ( click the link to review the publication )

Cancer Discov, 2013, 4(2):186-99

PubMed: 24302555 ( click the link to review the publication )

Cell, 2012, 27;149(3):656-70.

PubMed: 22541435 ( click the link to review the publication )

Nat Med, 2012, 18(6):892-901

PubMed: 22610277 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 33(1):108221

PubMed: 33027668 ( click the link to review the publication )

Sci Signal, 2020, 3;13(621) pii: eaax2364

PubMed: 32127496 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2500

PubMed: 32899250 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-01074-2

PubMed: 32963347 ( click the link to review the publication )

Mol Cancer Res, 2020, 11

PubMed: 32161139 ( click the link to review the publication )
Sci Rep, 2020, 10(1):16208

PubMed: 33004905 ( click the link to review the publication )

Front Neurosci, 2020, 2;14:223

PubMed: 32300287 ( click the link to review the publication )

Eur J Pharmacol, 2020, 870:172821

PubMed: 31770526 ( click the link to review the publication )

Cell Biol Int, 2020, 10.1002/cbin.11322

PubMed: 32068318 ( click the link to review the publication )

Turk J Haematol, 2020, 37(3):167-176

PubMed: 32160736 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):724

PubMed: 32758183 ( click the link to review the publication )

FASEB Bioadv, 2020, 2(2):126-144

PubMed: 32123862 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12673

PubMed: 32191822 ( click the link to review the publication )

Cancer, 2020, 10.1002/cncr.33071

PubMed: 32767682 ( click the link to review the publication )

Small GTPases, 2020, 10.1080/21541248

PubMed: 32043900 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(2):226-237

PubMed: 30692625 ( click the link to review the publication )

Nat Commun, 2019, 10(1):259

PubMed: 30651547 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2910

PubMed: 31266951 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1515

PubMed: 30944303 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(6):1061-1076

PubMed: 30825612 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0556-z

PubMed: 31462739 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Theranostics, 2019, 9(8):2380-2394

PubMed: 31149050 ( click the link to review the publication )

Cell Rep, 2019, 27(1):294-306

PubMed: 30943409 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2317-2330

PubMed: 31461649 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0422-6

PubMed: 31570855 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )
Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Mol Ther Oncolytics, 2019, 13:58-66

PubMed: 31016228 ( click the link to review the publication )

Cancer Discov, 2019, 9(9):1306-1323

PubMed: 31217297 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):834-844

PubMed: 30787173 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(18):7780-7795

PubMed: 31545294 ( click the link to review the publication )

J Cell Physiol, 2019, 234(7):10907-10917

PubMed: 30536897 ( click the link to review the publication )

Front Oncol, 2019, 0.87569444444

PubMed: 31428587 ( click the link to review the publication )

Front Oncol, 2019, 9:1119

PubMed: 31750239 ( click the link to review the publication )

Eur J Immunol, 2019, doi: 101002/eji201948241

PubMed: 31621069 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

Chem Biol Interact, 2019, 302:101-107

PubMed: 30703376 ( click the link to review the publication )

Eur J Pharmacol, 2019, 842:89-98

PubMed: 30401630 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 513(3):546-552

PubMed: 30981504 ( click the link to review the publication )

Leuk Lymphoma, 2019, 10.1080/10428194.2019.1594211

PubMed: 30947576 ( click the link to review the publication )

Int J Hematol, 2019, 110(2):213-227

PubMed: 31129802 ( click the link to review the publication )

Oncol Lett, 2019, 17(3-:3151-3162

PubMed: 30867745 ( click the link to review the publication )

NPJ Breast Cancer, 2019, 05:31

PubMed: 31552290 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Nat Protoc, 2018, 13(12):2827-2843

PubMed: 30382243 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4550

PubMed: 30382095 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1357

PubMed: 29636477 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(5)

PubMed: 29650805 ( click the link to review the publication )
Cancer Res, 2018, 78(8):2000-2013

PubMed: 29437705 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )

NPJ Genom Med, 2018, 3:15

PubMed: 29951225 ( click the link to review the publication )

Cancer Res, 2018, 78(14):4007-4021

PubMed: 29760046 ( click the link to review the publication )

Cell Rep, 2018, 24(8):2155-2166

PubMed: 30134175 ( click the link to review the publication )

Cell Rep, 2018, 24(2):463-478

PubMed: 29996106 ( click the link to review the publication )

Elife, 2018, 7e33718

PubMed: 30475204 ( click the link to review the publication )

Int J Cancer, 2018, 143(5):1188-1201

PubMed: 29582409 ( click the link to review the publication )

Int J Cancer, 2018, 142(9):1926-1937

PubMed: 29210065 ( click the link to review the publication )

Oncogene, 2018, 37(3):363-376

PubMed: 28945225 ( click the link to review the publication )

Cancer Lett, 2018, 439:56-65

PubMed: 30243708 ( click the link to review the publication )

Sci Signal, 2018,

PubMed: 29535262 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Oncol Rep, 2018, 40(6):3223-3234

PubMed: 30272286 ( click the link to review the publication )

Oncol Rep, 2018, 40(1):479-487

PubMed: 29767248 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

Oncol Lett, 2018, 15(3):3321-3328

PubMed: 29435074 ( click the link to review the publication )

Oncotarget, 2018, 9(56):30869-30882

PubMed: 30112114 ( click the link to review the publication )

J Exp Med, 2018, 215(1):159-175

PubMed: 29141866 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Mol Cell, 2017, 65(6):999-1013

PubMed: 28306514 ( click the link to review the publication )

Nat Commun, 2017, 8:15623

PubMed: 28585535 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )
Nat Commun, 2017, 8:15021

PubMed: 28443643 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Dev Cell, 2017, 43(6):673-688

PubMed: 29103956 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(41):E8628-E8636

PubMed: 28973876 ( click the link to review the publication )

Cancer Res, 2017, 77(16):4448-4459

PubMed: 28652248 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163

PubMed: 28119489 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1779-1790

PubMed: 28619753 ( click the link to review the publication )

Mol Cell Proteomics, 2017, 16(10):1864-1888

PubMed: 28794006 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

SLAS Discov, 2017, 22(8):974-984

PubMed: 28644734 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28977994 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52474-52487

PubMed: 28881745 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(13):21806-21817

PubMed: 28423521 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29137323 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6608-6622

PubMed: 28036259 ( click the link to review the publication )

Oncotarget, 2017, 8(44):76935-76948

PubMed: 29100359 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(12):1324-1335

PubMed: 27870828 ( click the link to review the publication )

Blood, 2016, 127(10):1325-35

PubMed: 26668133 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(3):644-56.

PubMed: 26224873 ( click the link to review the publication )

PLoS Biol, 2016, 14(11):e1002581

PubMed: 27880766 ( click the link to review the publication )

Cancer Res, 2016, 76(24):7168-7180

PubMed: 27913436 ( click the link to review the publication )
Cell Rep, 2016,

PubMed: 27292631 ( click the link to review the publication )

J Hematol Oncol, 2016, 9(1):113

PubMed: 27765055 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

J Transl Med, 2016, 14:56

PubMed: 26912358 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 79:308-317

PubMed: 27599915 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0147682

PubMed: 26821351 ( click the link to review the publication )

PLoS One, 2016, 10.1371/journal

PubMed: 27055253 ( click the link to review the publication )

Oncotarget, 2016, 7(41):67277-67287

PubMed: 27572309 ( click the link to review the publication )

Nature, 2016, 529(7586):413-417

PubMed: 26735014 ( click the link to review the publication )

Oncotarget, 2016, 7(26):40398-40417

PubMed: 27259258 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )

Sci Rep, 2016, 6:20189

PubMed: 26846842 ( click the link to review the publication )

Oncotarget, 2016, 7(45):72608-72621

PubMed: 27579615 ( click the link to review the publication )

J Clin Invest, 2015, 10.1172/JCI78018

PubMed: 25798617 ( click the link to review the publication )

J Clin Invest, 2015, 125(12):4559-71

PubMed: 26529251 ( click the link to review the publication )

Genes Dev, 2015, 29(16):1677-82

PubMed: 26272820 ( click the link to review the publication )

Cancer Res, 2015, 75(14):2851-62

PubMed: 25977330 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.173

PubMed: 25982275 ( click the link to review the publication )

Glia, 2015, 63(10):1850-9

PubMed: 25944104 ( click the link to review the publication )

Biomed Pharmacother, 2015, 75:40-50

PubMed: 26463630 ( click the link to review the publication )

Acta Pharmacol Sin, 2015, 10.1038/aps.2015.4

PubMed: 25864651 ( click the link to review the publication )

Cell Signal, 2015, 27(12):2389-400

PubMed: 26363466 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: 25704758 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: ( click the link to review the publication )
Int J Biochem Cell Biol, 2015, 60C:34-42

PubMed: 25578563 ( click the link to review the publication )

Int Immunopharmacol, 2015, 28(1):675-85

PubMed: 26256696 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0133610

PubMed: 26402468 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Immunol Res, 2015, 10.1007/s12026-015-8648-y

PubMed: 25869396 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Crit Rev Oncol Hematol, 2015,

PubMed: 26253360 ( click the link to review the publication )

J Clin Invest, 2014, 124(12):5490-502

PubMed: 25401474 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

J Exp Med, 2014, 211(13):2497-2505

PubMed: 25488980 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Rep, 2014, 8(5):1265-70

PubMed: 25176649 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

PLoS Pathog, 2014, 10(6):e1004196

PubMed: 24945378 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(1):R9

PubMed: 24451154 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(10):1520-31

PubMed: 25103499 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

PLoS One, 2014, 9(10):e108780

PubMed: 25360799 ( click the link to review the publication )

PLoS One, 2014, 9(7):e101969

PubMed: 25003333 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )

Oncotarget, 2014, 5(14):5295-303

PubMed: 24979463 ( click the link to review the publication )
Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(21):5940-51

PubMed: 23918606 ( click the link to review the publication )

Cancer Res, 2013, 73(17):5459-72

PubMed: 23796563 ( click the link to review the publication )

Oncogene, 2013, 10.1038/onc.2013.509

PubMed: 24292683 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(4):R55

PubMed: 23844554 ( click the link to review the publication )

Cell Commun Signal, 2013, 11(1):3

PubMed: 23311350 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1269-78

PubMed: 23814023 ( click the link to review the publication )

BMC Cancer, 2013, 13:465

PubMed: 24103747 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

University Gattingen, 2013, Elisabeth Hand

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	Vps34 ^[1] (Cell-free assay)	View More
52 nM	116 nM	166 nM	262 nM	2.4 μM	View More

In vitro

BKM120 is not sensitive to Class III and Class IV PI3K's or PI4K. NVP-BKM120 shows great antiproliferation activity to PI3K deregulated cell lines including A2780, U87MG, MCF7 and DU145 with GI50 of 0.1-0.7 nM. ^[1] BKM120 induces multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266) apoptosis, which results in increased G1-phase cells and decreased S-phase cells. BKM120 induced CD138+ primary MM cell apoptosis and has significant lower cytotoxicity toward CD138− stromal cells. BKM120 exposure could cause upregulation of BimS and downregulation of XIAP. ^[2] BKM120 demonstrates antiproliferative activity in human gastric cancer cell lines by decreasing mTOR downstream signaling. BKM120 could increase either p-ERK or p-STAT3 in KRAS mutant gastric cancer cells. Combination with STAT3 blockade, BKM120 shows a synergism in cells harboring mutated KRAS by inducing apoptosis, but not in KRAS wild-type cells. ^[3] A recent study shows that BKM120 shows differential forms of cell death on the basis of p53 status of the cells with p53 wild-type cells undergoing apoptotic cell death and p53 mutant/deleted cells having a mitotic catastrophe cell death. BKM120 mediates mitotic catastrophe mainly through Aurora B kinase. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MCF7	NXL1[Yl{S3m2b4TvfIlkKEG\|c3H5		M4HSUFczKGh?	M{\WXWROW09?	NFrVSJREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGW6cILld5NqdmdiUFmzT4FteGijIFW1OFVMKG23dHHueEB4cXSqIFfJOVAhd2ZiMD6wNFAyPThizszN	NG\J[GUzPDlyMEK2Oi=>
DU145	MnXmR5l1d3SxeHnjJGF{e2G7		MlHDO\|IhcA>?	NW\DUINSTE2VTx?=	NFjUZ2dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCneIDy[ZN{cW6pIFzLRlEhdXW2YX70JJdqfGhiR1m1NEBw\iByLkCwNFQ{PSEQvF2=	NF6xS2ozPDlyMEK2Oi=>
A2780	M3TJ[WN6fG:2b4jpZ{BCe3OjeR?=		M4PTbFczKGh?	MVHEUXNQ	M4r0SmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCWRV6t[IVncWOrZX70JIh2dWGwIFGyO\|gxKGOnbHzzJJdqfGhiR1m1NEBw\iByLkCwNFY{PSEQvF2=	MljONlQ6ODB{Nk[=
U87MG	NXPqVpluS3m2b4TvfIlkKEG\|c3H5		MXe3NkBp	MXrEUXNQ	Mnn2R5l1d3SxeHnjbZR6KGGpYXnud5QhWFSHTj3k[YZq[2mnboSgbJVu[W5iVUi3UWch[2WubIOge4l1cCCJSUWwJI9nKDBwMECwOlk5KM7:TR?=	NVvkNot5OjR7MECyOlY>
A2780	MVPGeY5kfGmxbjDBd5NigQ>?		Mkj5NUBp	NVGybpp7TE2VTx?=	M37MW2lvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6wOVUh\|ryP	MXOyOFkxODJ4Nh?=
DU145	NE\jSnVHfW6ldHnvckBCe3OjeR?=		MUixJIg>	MmO4SG1UVw>?	MY\Jcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gSHUyPDViY3XscJMhcGG{Yn;ybY5oKEyNQkGgcZV1[XSrb36ge4l1cCCHQ{WwJI9nKDBwMEezJO69VQ>?	MlKxNlQ6ODB{Nk[=
A2780	NH75OZFHfW6ldHnvckBCe3OjeR?=		M2GxUFEhcA>?	M1m3RmROW09?	NI\MdJRKdmirYnn0bY9vKG:oIGDJN2sudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hcW5iUGTFUk1l\W[rY3nlcpQhcHWvYX6gRVI4QDBiY3XscJMhf2m2aDDFR\|UxKG:oIECuNFc1KM7:TR?=	NXHINGl6OjR7MECyOlY>
MCF7	NVvqc5Z{TnWwY4Tpc44hSXO\|YYm=		MVGxJIg>	NEHsR2ZFVVOR	MkXGTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiRUW0OWshdXW2YX70MY1m\GmjdHXkJGFMXCCVZYK0O\|MheGixc4Doc5J6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkGg{txO	M2G5cFI1QTByMk[2
U87MG	NF64ZllHfW6ldHnvckBCe3OjeR?=		NX35OGFuOSCq	MXHEUXNQ	MXzJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:\|cHjvdplt[XSrb36gbY4hWFSHTj3k[YZq[2mnboSgbJVu[W5iVUi3UWch[2WubIOge4l1cCCHQ{WwJI9nKDBwMUOg{txO	MUWyOFkxODJ4Nh?=
A2780	M3\CeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUOyOIkzPzJiaB?=	NWPqPW5KTE2VTx?=	MoDQSWM2OD1yLkWyJO69VQ>?	NULhbWRPOjR7MECyOlY>
SKMES-1	MoHrR5l1d3SxeHnjJGF{e2G7	M3L1fFEh\|ryP	M4TpRVczKGh?		NEXHV2NKdmS3Y3XzJINmdGxiZHXheIg>	NF3IelMzPjBzM{OxPC=>
H596	NUXuUGtuTnWwY4Tpc44hSXO\|YYm=	MWSxJO69VQ>?			NWnuNo53UW2yYXnyd{Bk\WyuIH3p[5JifGmxbh?=	M1fwPVI3ODF\|M{G4
HCC2450	M2TxO2Z2dmO2aX;uJGF{e2G7	M2fkdFEh\|ryP			MX7JcZBicXK\|IHPlcIwhcW64YYPpc44>	MXSyOlAyOzNzOB?=
A549	MlXRSpVv[3Srb36gRZN{[Xl?	M13KTFUxOCCwTR?=	MYW0PEBp	NVPjNZcyTE2VTx?=	NIWyTWdKdmirYnn0d{BCc3RiYXP0bZZifGmxbh?=	NY[2TYVpOjV7M{eyPVk>
A549	NWfaRnZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\GVVEh\|ryP	Mn\MO\|IhcA>?	NEK0R2RFVVOR	MVvJcohq[mm2czDj[YxtKGe{b4f0bC=>	MVmyOVk{PzJ7OR?=
H522	NFjaTXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX:xJO69VQ>?	NWHlS2M6PzJiaB?=	NILYXXFFVVOR	MmrTTY5pcWKrdIOgZ4VtdCCpcn;3eIg>	MorUNlU6Ozd{OUm=
LNCaP	NH3oZZZHfW6ldHnvckBCe3OjeR?=	NYfWWYd1OSEQvF2=			M4nWPHN2eHC{ZYPz[ZMheC2DS2SgcIV3\Wy\|	M1HGOlI2OzZyN{m5
LNCaP95	NEH2ToxHfW6ldHnvckBCe3OjeR?=	M{TP[\|Eh\|ryP			MmX6V5VxeHKnc4Pld{BxNUGNVDDs[ZZmdHN?	M1\kVFI2OzZyN{m5
HCT-15	NEjyVJRCeG:2b4Ppd{BCe3OjeR?=	MojUNVAh\|ryP	MoDJOFghcA>?	MoL1SG1UVw>?	MkK0TY5lfWOnczDhdI9xfG:\|aYOgbY4hUEOWLUG1JINmdGy\|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25?	Ml34NlUyPTJ{NEW=
HCT-116	MUXBdI91d3OrczDBd5NigQ>?	NXHsbpNvOTBizszN	MnSzOFghcA>?	M3rlUWROW09?	MYnJcoR2[2W\|IHHwc5B1d3OrczDpckBJS1RvMUG2JINmdGy\|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25?	MXOyOVE2OjJ2NR?=
NCI-H460	M4TZWWFxd3Sxc3nzJGF{e2G7	M2jZXFExKM7:TR?=	M3\UOlQ5KGh?	NHvKdndFVVOR	NETTPG1KdmS3Y3XzJIFxd3C2b4Ppd{BqdiCQQ1mtTFQ3OCClZXzsd{Bp[XKkb4XybY5oKFCLS{PDRUBpd3S\|cH;0JI12fGG2aX;u	MU[yOVE2OjJ2NR?=
SKOV-3	NWDzOJA2SXCxdH;zbZMhSXO\|YYm=	NHjHTY8yOCEQvF2=	NW\QfIJxPDhiaB?=	Ml6wSG1UVw>?	MYXJcoR2[2W\|IHHwc5B1d3OrczDpckBUU0:YLUOgZ4VtdHNiaHHyZo92emmwZzDQTWs{S0FiaH;0d5BwfCCvdYTheIlwdg>?	NXXpN3dYOjVzNUKyOFU>
BSY-1	MUfBdI91d3OrczDBd5NigQ>?	M1LpWFExKM7:TR?=	Ml\qOFghcA>?	MnHwSG1UVw>?	NFfXNWtKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCEU2mtNUBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w	NITCSVgzPTF3MkK0OS=>
MKN-1	NXjRVIpOSXCxdH;zbZMhSXO\|YYm=	MVSxNEDPxE1?	MXm0PEBp	NGG4TFFFVVOR	NWPsUYI2UW6mdXPld{BieG:ydH;zbZMhcW5iTVvOMVEh[2WubIOgbIFz[m:3cnnu[{BRUUt\|Q1GgbI91e3CxdDDteZRifGmxbh?=	NUL6R5FDOjVzNUKyOFU>
NCI-H522	MUPBdI91d3OrczDBd5NigQ>?	MYKxNEDPxE1?	M3\sUFQ5KGh?	M2G0fWROW09?	M4myUWlv\HWlZYOgZZBweHSxc3nz	MmO3NlUyPTJ{NEW=
OVCAR-3	M2fHZWFxd3Sxc3nzJGF{e2G7	NIXibG0yOCEQvF2=	NXTSS4k2PDhiaB?=	M{HrT2ROW09?	NHLEbXZKdmS3Y3XzJIFxd3C2b4Ppdy=>	NV;Fe3dIOjVzNUKyOFU>
HBC-5	M2fRbGFxd3Sxc3nzJGF{e2G7	MW[xNEDPxE1?	NHPRSIQ1QCCq	MmnNSG1UVw>?	Mn:4TY5lfWOnczDhdI9xfG:\|aYO=	M1fzTVI2OTV{MkS1
RXF-631L	NX;iNYFQSXCxdH;zbZMhSXO\|YYm=	MUmxNEDPxE1?	MWq0PEBp	MXrEUXNQ	MULJcoR2[2W\|IHHwc5B1d3Orcx?=	NHfwNJYzPTF3MkK0OS=>
MKN-45	M1e2bGFxd3Sxc3nzJGF{e2G7	M2jTRVExKM7:TR?=	MmPCOFghcA>?	NV76TVFoTE2VTx?=	NWD2XHBwUW6mdXPld{BieG:ydH;zbZM>	NETMcFAzPTF3MkK0OS=>
BON-1	M3vtPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfiOGY2ODBibl2=	M4CyWlExKGR?	M{naW2ROW09?	M2jz[mlvcGmkaYTzJINmdGxiZ4Lve5Rp	NF\ydFgzPTB{NkK5Ni=>
BON-1	M{PjZ2Z2dmO2aX;uJGF{e2G7	NEXwVHo2ODBibl2=	NVfQZ2hHPCCq	M4X0cWROW09?	NWHzTI57UW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBVcHJ\|MEigZY5lKFOnckS3Ny=>	MVKyOVAzPjJ7Mh?=
QGP-1	M{TwSGZ2dmO2aX;uJGF{e2G7	M4nid\|UxOCCwTR?=	NGPtSnY1KGh?	MXLEUXNQ	Mm\DTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDUbJI{ODhiYX7kJHNmejR5Mx?=	M1vMVVI2ODJ4Mkmy
Huh7	NHP2fIpHfW6ldHnvckBCe3OjeR?=	NIHhN5YyKM7:TR?=	Ml:yNUBp	MUHEUXNQ	NVLU[YhKUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBU\XJ2N{S=	MYSyOVAxPDRyMx?=
BNL	MoLtSpVv[3Srb36gRZN{[Xl?	NGH2c24yKM7:TR?=	M2TSNFEhcA>?	MXHEUXNQ	M1fQbGlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBUPg>?	M{Lyb\|I2ODB2NECz
MDA-MB-175	MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnH[ZkyKM7:TR?=	MU[1JIQ>	NX\XcIlrTE2VTx?=	Ml\YTWM2ODxzIN88US=>	NXfHWVlWOjR6N{m3PVY>
MDA-MB-134	NVTvXmhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTp[nIyKM7:TR?=	Mn[yOUBl	M4W3bGROW09?	MYXJR\|UxRDFizszN	Mme3NlQ5Pzl5OU[=
HCC1500	M2\sNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW[xJO69VQ>?	NGrTdJU2KGR?	M4XoPWROW09?	NX:xOJp5UUN3MEyxJO69VQ>?	NGTVbGMzPDh5OUe5Oi=>
EFM-19	MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLiNUDPxE1?	MnLlOUBl	M3jN[mROW09?	M{LQO2lEPTB:MTFOwG0>	NE\YSJozPDh5OUe5Oi=>
ZR-75-30	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{T0fVEh\|ryP	MV21JIQ>	NInPdXJFVVOR	M2nGU2lEPTB:MTFOwG0>	NGLF[\|YzPDh5OUe5Oi=>
MDA-MB-361	MmT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3ne2w3OSEQvF2=	MU[1JIQ>	M2LxRmROW09?	M2HsUmlEPTB:MTFOwG0>	MYiyOFg4QTd7Nh?=
T-47D	NFG5c3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXDdm04OSEQvF2=	NX\BXIFwPSCm	M1PpeGROW09?	MnnBTWM2ODxzIN88US=>	NVrG[WZLOjR6N{m3PVY>
SK-BR-3	M3PKSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILCdWYyKM7:TR?=	NXrUd3lsPSCm	M3;SOmROW09?	NV64cHU4UUN3MEyxJO69VQ>?	NXLTcmdlOjR6N{m3PVY>
UACC-732	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljvNUDPxE1?	M1;GdFUh\A>?	M2q5V2ROW09?	M1vFb2lEPTB:MTFOwG0>	NFP6VpIzPDh5OUe5Oi=>
BT-474	NYDtdmg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPSNUDPxE1?	MWK1JIQ>	M2S2V2ROW09?	NHHHfmRKSzVyPEGg{txO	M{TVeVI1QDd7N{m2
HCC202	NIX3THdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTWNUDPxE1?	MYK1JIQ>	NFz5ZYxFVVOR	MoiyTWM2ODxzIN88US=>	NHnCPVAzPDh5OUe5Oi=>
MCF7	NFLFbpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYqxJO69VQ>?	MWO1JIQ>	NWrIbVlyTE2VTx?=	M3XqSGlEPTB:MTFOwG0>	NYfFNWJ3OjR6N{m3PVY>
MDA-MB-415	NEjnVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGracnoyKM7:TR?=	M2rIPVUh\A>?	NH63cFBFVVOR	MWjJR\|UxRDFizszN	MlXpNlQ5Pzl5OU[=
MDA-MB-453	MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDnbIMyKM7:TR?=	Mn;COUBl	NUXUXYJGTE2VTx?=	M2rubWlEPTB:MTFOwG0>	MVGyOFg4QTd7Nh?=
ZR-75-1	MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\RNFEh\|ryP	M2nuSVUh\A>?	M{PsT2ROW09?	NYDVeWN2UUN3MEyxJO69VQ>?	NWj4VnVmOjR6N{m3PVY>
HCC38	M3LFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\SNUDPxE1?	NVTzdI1wPSCm	NWXVd45OTE2VTx?=	NGK4UGhKSzVyPEGg{txO	NELYVI4zPDh5OUe5Oi=>
HCC1419	NFnPVmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3neXNsOSEQvF2=	MXS1JIQ>	MlTGSG1UVw>?	MUDJR\|UxRDFizszN	NVWyXmdLOjR6N{m3PVY>
UACC-812	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYCxJO69VQ>?	NFX1cVA2KGR?	NXj4dpE{TE2VTx?=	NYHxZ\|lsUUN3MEyxJO69VQ>?	MWOyOFg4QTd7Nh?=
HCC1187	NFXJRm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M364e\|Eh\|ryP	MWq1JIQ>	NGDJVmFFVVOR	MmXoTWM2ODxzIN88US=>	NImwRXQzPDh5OUe5Oi=>
KPL-1	NETMeWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn2xNUDPxE1?	NXLJWJhNPSCm	MVrEUXNQ	MXjJR\|UxRDFizszN	NXrFcYNiOjR6N{m3PVY>
SUM-225	NH7QRYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjP[G8yKM7:TR?=	Mlj2OUBl	MlvtSG1UVw>?	NXju[IdjUUN3MEyxJO69VQ>?	M{[xNVI1QDd7N{m2
EFM-192A	M1f3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;RSppyOSEQvF2=	MYe1JIQ>	Ml2xSG1UVw>?	MY\JR\|UxRDFizszN	MYeyOFg4QTd7Nh?=
JIMT-1	M2\x[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYKxJO69VQ>?	M2\mTFUh\A>?	M122cGROW09?	NX33NZJQUUN3MEyxJO69VQ>?	NIHzXVIzPDh5OUe5Oi=>
HCC1143	NUnVXGlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1r6SFEh\|ryP	M{K0S\|Uh\A>?	NYPyc285TE2VTx?=	M3O2cWlEPTB:MTFOwG0>	MU[yOFg4QTd7Nh?=
HCC2218	NIP2b25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfRcYlLOSEQvF2=	MY[1JIQ>	NVTNe3RZTE2VTx?=	M1\I[GlEPTB:MTFOwG0>	NIC1b2EzPDh5OUe5Oi=>
MDA-MB-468	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXixJO69VQ>?	MX21JIQ>	NV\WTmlITE2VTx?=	MW\JR\|UxRDFizszN	NIPvU\|AzPDh5OUe5Oi=>
BT-20	NUDre2JvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVu5SoxGOSEQvF2=	MlrHOUBl	M3PibGROW09?	MYXJR\|UxRDFizszN	MWOyOFg4QTd7Nh?=
MDA-MB-435	M1\JfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvofFJtOSEQvF2=	NYfweY9PPSCm	M4jvUWROW09?	NIPib2JKSzVyPEGg{txO	M{P0WlI1QDd7N{m2
BT-549	MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV6xJO69VQ>?	NHLCTFg2KGR?	M{HROWROW09?	NWLtfWxjUUN3MEyxJO69VQ>?	NH60UI8zPDh5OUe5Oi=>
HCC1806	NUPXe2plT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nLZ\|Eh\|ryP	NHHzNWI2KGR?	MWPEUXNQ	M{P1d2lEPTB:MTFOwG0>	NFSzdYgzPDh5OUe5Oi=>
HCC1937	NWnvN2ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17jOlEh\|ryP	NEj4TGU2KGR?	MnmxSG1UVw>?	M{PlfGlEPTB:MTFOwG0>	MlXrNlQ5Pzl5OU[=
Hs578T	MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jOdVEh\|ryP	MWi1JIQ>	NVXEW5I6TE2VTx?=	M2TGc2lEPTB:MTFOwG0>	M3GwWlI1QDd7N{m2
LN18	MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTiNlAh\|ryP	MlfSO\|IhcA>?	MnnMSG1UVw>?	MmLFTWM2ODx3IN88US=>	M13o[VI1PzRzMEe0
LN229	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7rPVQzOCEQvF2=	MX23NkBp	NX7VNI1PTE2VTx?=	MoHZTWM2ODx3IN88US=>	M1LLbVI1PzRzMEe0
LNZ308	NYDUdGhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTsUo0zOCEQvF2=	M3ixSFczKGh?	NFTZZ3dFVVOR	NHzTXFNKSzVyPEWg{txO	MorlNlQ4PDFyN{S=
T98G	Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU[yNEDPxE1?	NHPSR4s4OiCq	MYLEUXNQ	NWnWZWx6UUN3MEy1JO69VQ>?	NI\6XmIzPDd2MUC3OC=>
U87	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLRPWMzOCEQvF2=	MlPQO\|IhcA>?	MVrEUXNQ	NFq1U5hKSzVyPEWg{txO	M1HOcFI1PzRzMEe0
LN18	MYTGeY5kfGmxbjDBd5NigQ>?	M3XFelUh\|ryP	NV7GT4N3OjRiaB?=	M4PabWROW09?	MV7Jcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtV	MnHiNlQ4PDFyN{S=
LNZ308	MXzGeY5kfGmxbjDBd5NigQ>?	MmDpOUDPxE1?	M4\UfFI1KGh?	MVHEUXNQ	Mo\KTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>?	MUeyOFc1OTB5NB?=
Saos-2	M{X5fGZ2dmO2aX;uJGF{e2G7	Mlr5OVAh\|ryP	NEGzc481QCCq		NY\rU\|U1UW6qaXLpeJMh[2WubDDpcpZie2mxbh?=	MnvKNlQ4Ojd4NkC=
MG-63	M3LafmZ2dmO2aX;uJGF{e2G7	M4jnTVUxKM7:TR?=	NVnSPVR2PDhiaB?=		NF76OZRKdmirYnn0d{Bk\WyuIHnueoF{cW:w	MnXGNlQ4Ojd4NkC=
SJSA-1	NFjqVVhHfW6ldHnvckBCe3OjeR?=	MUO1NEDPxE1?	MmriOFghcA>?		NVixOm5iUW6qaXLpeJMh[2WubDDpcpZie2mxbh?=	MXmyOFczPzZ4MB?=
Saos-2	NUe1TYV1TnWwY4Tpc44hSXO\|YYm=	MXK1NEDPxE1?	MnTqOFghcA>?		NWTaZnhFUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>?	MlXQNlQ4Ojd4NkC=
MG-63	Moq2SpVv[3Srb36gRZN{[Xl?	NYW0OG9oPTBizszN	MmfKOFghcA>?		M1e4SmlvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG\|ZT2yJIV5eHKnc4Ppc44>	MWqyOFczPzZ4MB?=
SJSA-1	MmPlSpVv[3Srb36gRZN{[Xl?	MmPrOVAh\|ryP	NFPsdXc1QCCq		M1;xe2lvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG\|ZT2yJIV5eHKnc4Ppc44>	MY[yOFczPzZ4MB?=
Saos-2	NEjSZoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVz2ZW9HPTBizszN	NVy5N2poPDhiaB?=		NHLiUopKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?=	MUiyOFczPzZ4MB?=
MG-63	NXXNcXpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LlVVUxKM7:TR?=	MV:0PEBp		M1XjPGlvcGmkaYTzJINmdGxidnnhZoltcXS7	NIr2coIzPDd{N{[2NC=>
SJSA-1	NGrFdYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrJT4E2OCEQvF2=	Ml61OFghcA>?		MUjJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?	M{TFcFI1PzJ5Nk[w
FaDu	M4rKfGZ2dmO2aX;uJGF{e2G7	M17ZelUh\|ryP	NVzpUYVsOjRiaB?=	Ml3kSG1UVw>?	NWT1bYNoWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44>	M3ftWlI1PjNzMUS3
EMT6	M{\kOmZ2dmO2aX;uJGF{e2G7	M2noVVUh\|ryP	MW[yOEBp	NHe1SlFFVVOR	M{T2bXJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u	NXXJbmpiOjR4M{GxOFc>
HCT116	NUPiWWp2TnWwY4Tpc44hSXO\|YYm=	MkXBOUDPxE1?	M{PaTVI1KGh?	M4e4Z2ROW09?	M4m0V3Jm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u	NYTOU5lROjR4M{GxOFc>
U87	NWnnVFc4TnWwY4Tpc44hSXO\|YYm=	M{PhS\|Uh\|ryP	MlXlNlQhcA>?	NYH6ZVNbTE2VTx?=	M2fLW3Jm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u	MWWyOFY{OTF2Nx?=
GBM	MWXBdI9xfG:\|aYOgRZN{[Xl?	MYmy{txO	MkD6OFhp	Mn;6SG1UVw>?	Mn;QbY5lfWOnZDDobYdp\XJibHX2[Yx{KG:oIHHwc5B1d3OrczygZY5lKGSnY4LlZZNm\CClZXzsJJZq[WKrbHn0fS=>	M1:0dVI1PTByNEmy
BON	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU[xMVXPxE1?	M1PmfFczcA>?		MnG4[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvci=>	NFu3bngzPDR2M{WyNy=>
BON	M2PDUGFxd3C2b4Ppd{BCe3OjeR?=	NGXlZYwyNTYQvF2=	M3vCTVI1cA>?		M4n6PYlv[3KnYYPld{BieG:ydH;zbZM>	NWr5bFFnOjR2NEO1NlM>
H1975	NWrqd3hrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW[wMlMuQS54zszN	NUfWR5pKPzKq	NIDPXpZFVVOR	M1XFPGlEPTB;MT6zPFXPxE1?	MXuyOFM{Pzh2Nh?=
H1975	MnrZRZBweHSxc3nzJGF{e2G7	M3Xtd\|LPxE1?	M3;ZdlI1cA>?	NU\2OnJFTE2VTx?=	NYPoblJscW6lcnXhd4V{KGGyb4D0c5NqeyC{YYTlJJNq\26rZnnjZY51dHl?	MVqyOFM{Pzh2Nh?=
T-ALL	MnvaRZBweHSxc3nzJGF{e2G7	MUHi[ZR4\WWwIEGuOEBidmRiNT6zJI1OKGG2IEK0bEBidmRiMD65JIFv\CB3LkWgcW0h[XRiNEjoJIlvKGSrZn\ldoVvfCClZXzsJIxqdmV?	M{DYWFI1KG:{IES4bC=>	Ml\zSG1UVw>?	NYDyN5lN[W[oZXP0d{B1cGViUFmzT{Bx[XSqd3H5JIlvKFRvQVzMJINmdGxibHnu[ZM>	M3jrZVI1OzFyN{O2
BCR-ABL	NIexd49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEX0VYYxNjJ3LUGw{txO	NEfRN4U1\A>?		MmT3d4lodmmoaXPhcpRtgSCrbnjpZol1KGOnbHygdJJwdGmoZYLheIlwdg>?	Mn;CNlQzPDR4MUK=
LC-1/SQSF	NEXnemdHfW6ldHnvckBCe3OjeR?=	NHXabpo{\|ryP	M4OwVVI1cA>?	MoC4SG1UVw>?	MVjk[YNz\WG\|ZTDOVmYzKHC{b4TlbY4hdGW4ZXy=	MXqyN\|k5ODB7Mx?=
Primary CLL cells	NF7Ie5FCeG:ydH;zbZMhSXO\|YYm=	MkL1NU0yOM7:TR?=	M3n5XFQ5cA>?		NELwNYpqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCFTFygZ4VtdHNiaX7k[ZBmdmSnboSgc4YheHKxZ37vd5Rq[yCvYYLr[ZJ{	M173PVI{QDVyOEC3
Primary CLL cells	MoniT4lv[XOnIFHzd4F6	NY[zW5dOOs7:TR?=	NVP3VZJSOzCvaX6=		MlzC[IVkemWjc3XkJHBKO0tiYXP0bZZqfHl?	NF3ERpYzOzh3MEiwOy=>
Primary CLL cells	NYLiVnZIS3m2b4TvfIlkKEG\|c3H5	MXqy{txO	NGjvb48zPGh?		M{TxPYlv\HWlZYOgZ4VtdCCleYTveI95cWOrdIm=	MmW2NlM5PTB6MEe=
human NSCLC cell lines	NXfl[YlqSXCxcITvd4l{KEG\|c3H5	MoLtNE4yOjVvNN88US=>	NXn1RmQzOjSq	MYLEUXNQ	NWrNW2JIUUN3MIOgdoFv\2W\|IH\yc40hOC52LUNOwG0>	Mlj6NlM2PjJ2N{K=
human HCC cell lines	M4rqS2NmdGxidnnhZoltcXS7IHHzd4F6	NWO1eGs1OC5yMEWtNe69VQ>?	NVT0SnJ[PDiq		MorPTWM2OD1zzszN	NYLoW\|Y4OjN2OEm5PVk>
Huh7	MUDLbY5ie2ViQYPzZZk>	M1nPeFHPxE1?	NXXySZBPPDiq		MWLzbYdvce,ugXPhcpRtgSC{ZXT1Z4V{KHCqb4PwbI9zgWyjdHnvckBw\iCDa4S=	MoTvNlM1QDl7OUm=
SK-HEP1	NGfpdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULzZVdsOS1{MN88US=>	NVzHb45DPzKq	MYfEUXNQ	NWK2eVg{UUN3MP-8oFHPxE1?	NFXWXnYzOzR5OUGzOi=>
786-0	NV7RZXNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWexMVIx\|ryP	NF6we2I4Omh?	MnvkSG1UVw>?	Mn36TWM2OO,:nEJOwG0>	MlHDNlM1PzlzM{[=
JVM2	NFfhWYlEgXSxdH;4bYNqfHliYYPzZZk>	MlTGNE4zNTJyzszN	NFvWfWs4Omh?	NVW4NVJtTE2VTx?=	MoDLTWM2OD1yLkpOwG0>	MmHvNlMzOzh4M{m=
EHEB	NXfMSG02S3m2b4TvfIlkcXS7IHHzd4F6	NFXZRYExNjJvMkFOwG0>	M1\Jd\|czcA>?	MYfEUXNQ	MkDlTWM2OD1yLkhOwG0>	NUHzfIpnOjN{M{i2N\|k>
MEC2	Mk\yR5l1d3SxeHnjbZR6KGG\|c3H5	NUPxXFJIOC5{LUKw{txO	NEXQPGM4Omh?	NIXwTo5FVVOR	M4HZ[2lEPTB;MD63{txO	MkPNNlMzOzh4M{m=
primary B-CLL lymphocytes	MnLrRZBweHSxc3nzJGF{e2G7	Mn;XTWM2OCCob4Kg[YFkcCCycnntZZJ6KGOnbHygcIlv\Q>?	MVyyOIg>	M17EUGROW09?	MVHJR\|Ux97zeM988UUBnd3JiYXzsJJBifGmnboTz	MmDHNlMzOzh4M{m=
primary B-CLL lymphocytes	MkXRT4lv[XOnIFHzd4F6	NF3sfWxKSzVyIH\vdkBm[WOqIIDybY1ienliY3XscEBtcW6n	NHy1TW8zPGh?		MYTpcohq[mm2czDwO\|BUPktiJjC0SU1DWDFiZYjwdoV{e2mxbh?=	NUi4XZg6OjN{M{i2N\|k>
human NSCLC	MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH:1VJMxNjVvMt88US=>	M4jwc\|czcA>?		NFfYOnJKSzVyPUJOwG0>	M4HocVIzPzhzM{mz
human NSCLC	NHP1UHlMcW6jc3WgRZN{[Xl?	M2TFOVHPxE1?	NGfVfHUzPGh?		MV;pcohq[mm2czD0bIUhSWu2L33UU3Ihe2mpbnHsbY5oKHCjdHj3ZZkh[XRiM3igZYZ1\XJidILlZZRu\W62	MlrHNlI4QDF\|OUO=
Y1 cell line	MoC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrYSHUxNjIQvF2vNe69VQ>?	M3HUV\|I1cA>?	MWfEUXNQ	MmPNbY5pcWKrdIOgOlDwxIViY3XscEB3cWGkaXzpeJkhcW5iTYnjMXNkfHJvdILhcpNn\WO2ZXSgZ4VtdHN?	NHniOWkzOjZ7MkmwOC=>
PIK3CA-mutant MCF7	NWK4e3Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVruTnFbT0l3ME2xOlDDuTlzbl5vwKxNTDVyPUm4NOKyOjd\|bl2=	MXy3Nog>		NI[3[3VIUTVyPUG2NOKyQTGwTf-8kGxFPTB;OUiwxtEzPzOwTR?=	M4e2eVIzPjV\|OU[3
PIK3CA-mutant MCF7	NULubY1bU2mwYYPlJGF{e2G7	MmfZTWM2OD1zMUVCtVNvVQ>?	MnO5O\|Jp		MlrqTWM2OD1zMUVCtVNvVSCrbjDy[YR2[2mwZzDBb5QheGixc4Doc5J6dGG2aX;uJIxmfmWucx?=	M3rtbVIzPjV\|OU[3
MCF7-myr-Akt	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInuXpRIUTVyPUK5PeKyPjiwTf-8kGxFPTExvK6xNEwxODCwTR?=	NF\XRWs4Omh?		M3vmfWdKPTB;Mkm5xtE3QG6P78{MUGQ2OO,:nkGwMFAxOG6P	M3nZWFIzPjV\|OU[3
colon cancer cell lines	NHzzTFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYSwMVEx\|ryP	MoO2O\|Jp	M4XlTWROW09?	MYLJR\|UxRTIQvF2=	NUKwZ\|BkOjJ3NEO4OVc>
gastric cancer cell lines	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLQNo8xNTFyzszN	NVHNWoZFPzKq	M4nyNmROW09?	MkftTWM2OD1{LUZOwG0>	NX62N5JkOjJ3NEO4OVc>
HCT-116/HT-29/MKN-45	M4LGR2Fxd3C2b4Ppd{BCe3OjeR?=	MV:y{txO	MYW0PIg>		M4n2cZNpcW[2IHnuJGczKHCqYYPl	M3PMd\|IzPTR\|OEW3
HT-29 and HCT-116	NXPP[YhJS2G\|cHHz[UBie3OjeR?=	MWO1{txO	M1fSdlI1cA>?		NHK5OnJqdmS3Y3XzJINie3Cjc3WgZYN1cX[rdIm=	NHrQVXkzOjV2M{i1Oy=>
MM cell lines	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVGxNO69VQ>?	NFLYfXEzPGh?	Mlf2SG1UVw>?	NUTvTJdJUUN3MDD2ZZJq\XNiYX3vcoch\GmoZnXy[Y51KGOnbHygcIlv\XNiaX6geIlu\SCjbnSg[I9{\SCmZYDlcoRmdmOn	M2e3NFIzOjB5NEi1
ARP-1	MYDBdI9xfG:\|aYOgRZN{[Xl?	MkDuNVDPxE1?	NHLXeXozPGh?	NHLG[HlFVVOR	M{PYWIlv\HWlZYOgUW0h[2WubDDhdI9xfG:\|aYOgeIhzd3WpaDDjZZNx[XOnIHHjeIl3[XSrb36=	MlvTNlIzODd2OEW=
SNU-601	NGjHUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUS0cJpvPzKq	M332ZmROW09?	MoL6TWM2OD1yLkixOuKyOC5yNkROwG0>	M1zYOlIzOTV7OEG0
SNU-1	M3PVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3v5UFczcA>?	M2jzW2ROW09?	M3nTW2lEPTB;MT6wPFLDuTBwMEK4{txO	MljRNlIyPTl6MUS=
SNU-668	M4O5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGKzVGc4Omh?	NEj6SZZFVVOR	M1zubGlEPTB;MT61O\|nDuTBwMEe0{txO	M4nXflIzOTV7OEG0
AGS	MnzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3jaNFczcA>?	M3W0[mROW09?	MoPSTWM2OD1zLkexOOKyOC5zMUhOwG0>	MYWyNlE2QThzNB?=
SNU-216	MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVK3Nog>	MV;EUXNQ	NGXU[4dKSzVyPUKuOlkzyrFyLkC4Nu69VQ>?	MnHHNlIyPTl6MUS=
SNU-5	M{jUU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXPDWJdxPzKq	MlXJSG1UVw>?	NEjUWphKSzVyPUGuN\|UyyrFyLkC5Ne69VQ>?	MlfuNlIyPTl6MUS=
SNU-638	M1H4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFHy[2Q4Omh?	M2HXTmROW09?	M4TYbWlEPTB;Mj6yPFLDuTBwMEWz{txO	NX7YO\|hQOjJzNUm4NVQ>
SNU-16	MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV3QXmxNPzKq	MV\EUXNQ	M33oVmlEPTB;MT61O\|PDuTBwMECx{txO	MWqyNlE2QThzNB?=
SNU-484	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkHUO\|Jp	NEXySINFVVOR	MXvJR\|UxRTFwN{K4xtExNjB2Nd88US=>	NXLScGh3OjJzNUm4NVQ>
SNU-620	MlnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{HhOFczcA>?	NULTUW42TE2VTx?=	M{nxZWlEPTB;Mj65N\|nDuTBwMECx{txO	MoPxNlIyPTl6MUS=
SNU-719	MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIXQb5I4Omh?	NX[0c5dZTE2VTx?=	NGjhUVRKSzVyPUOuNFM4yrFyLkCzNu69VQ>?	MnX0NlIyPTl6MUS=
glioma cell lines	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYjsRmRLPzKq		M{HjXmlEPTB;MT2y{txO	M2GxR\|IzODZ3MEiw
U87	NFOwb2hCeG:ydH;zbZMhSXO\|YYm=	MoXuNu69VQ>?	M2D0flczcA>?		M2O2Wolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiYX7kJINt\WG4ZXSgVGFTWCCjbnSgZ4F{eGG\|ZT2z	M1f4flIzODZ3MEiw

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT (T308) / p-AKT (S473) / AKT; PubMed: 27283525 J Neurooncol Left western blots showing levels of pAkt (T308), pAkt (S473) and total Akt in U87 cells exposed to buparlisib for 72 h. Right densitometric assessment of western blots, showing relative changes in phosphorylation. p-FOXO3a (S253) / FOXO3a; PubMed: 28036259 Oncotarget Cells were treated with 0.5 μM BKM120 for 24 h and cell lysates were immunoblotted with the indicated antibodies. Actin was used as the loading control. Nuclear NF-κB p65 / NF-κB p65; PubMed: 26673665 Cell Death Dis Western blots show BKM120 downregulating pAKT, nuclear NF-κB p65 and total NF-κB p65 in MDR and their parental cells. β-actin was used as a loading control for pAKT, AKT and total NF-κB p65. Lamin B was used as a loading control for nuclear NF-κB p65. p-ERK / ERK / LC3; PubMed: 27572309 Oncotarget The indicated cell lines were exposed to different concentrations of BKM120 as indicated for 8 h A. or with 2 μM BKM120 for the indicated times B. The cells were then harvested for preparation of whole-cell protein lysates and subsequent Western blot analysis to detect the given proteins. p-STAT3 / STAT3 / p-ERK / ERK / p-S6; PubMed: 29928341 Oncol Lett Western blot analysis of H460 and H2126 cell lysates using specific antibodies to phosphorylated or total proteins of STAT3, ERK1/2, AKT, S6 or GAPDH (loading control). The cells were treated with increasing concentrations of BKM120 for 24 h. p-MET / MET; PubMed: 29928341 Oncol Lett The expression of phosphorylated or total forms of MET protein was analyzed by western blotting.	27283525 28036259 26673665 27572309 29928341
Immunofluorescence	FOXO3a; PubMed: 28036259 Oncotarget Cells were cultured on coverslips to approximately 60% confluency and then treated with 1 μM BKM120 for an additional 24 h. Immunofluorescence staining was performed using an anti-FOXO3a antibody and the nuclei were stained with DAPI. Scale bar, 20 μm.	28036259
Growth inhibition assay	Cell viability; PubMed: 26673665 Cell Death Dis Dose-response curves were used to calculate the IC50 of BKM120 for MCs of MCF-7/A02 cells (upper) and CALDOX cells (lower).	26673665

In vivo

BKM120 completely inhibits pAktser473 in A2780 xenograft tumors at doses of 30, 60, or 100 mg/kg, respectively. BKM120 also shows antitumor activity against U87MG glioma model at doses of 30 and 60 mg/kg. ^[1] BKM120 treatment results in significantly reduced tumor volume and level of circulating human kappa chain at 5 μM/kg/day−1in ARP1 SCID mouse model, with prolonged survival. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse PI3K biochemical assay (ATP depletion assay): BKM120 is dissolved in DMSO and directly distributed into a black 384-well plate at 1.25 µL per well. To start the reaction, 25 µL of 10 nM PI3 kinase and 5 µg/mL 1-α-phosphatidylinositol (PI) in assay buffer (10 mM Tris pH 7.5, 5 mM MgCl₂, 20 mM NaCl, 1 mM DTT and 0.05% CHAPS) are added into each well followed by 25 µL of 2 µM ATP in assay buffer. The reaction is performed until approx 50% of the ATP is depleted and then stopped by the addition of 25 µL of KinaseGlo solution. The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence.
Cell Research:^[1]	- Collapse Cell lines: A2780 cells. Concentrations: 0-6.6 μM Incubation Time: 3 days. Method: A2780 cells are cultured in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 10³ cells per well, 100 μL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. BKM120 supplied in DMSO (20 mM) is diluted. The diluted BKM120 solution (2 μL), is then added to cell medium (500 μL) cell medium (concentration from 0-6.6 μM). Equal volumes of this solution (100 μL) are added to the cells in 96 well plates and incubated at 37 °C for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: U87MG and A2780 xenografts are established in female nu/nu mice. Dosages: ~60 mg/kg. Administration: Dosed orally daily (q.d.). (Only for Reference)

References

[4] Koul D, et al. Clin Cancer Res, 2012, 18(1), 184-195.

- Collapse

Solubility (25°C)

In vitro	DMSO	82 mg/mL (199.8 mM)
	Water	Insoluble
	Ethanol	'2 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Buparlisib (BKM120) SDF

Molecular Weight	410.39
Formula	C₁₈H₂₁F₃N₆O₂
CAS No.	944396-07-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	NVP-BKM120
Smiles	C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04338399	Not yet recruiting	Drug: Buparlisib & Paclitaxel	Head and Neck Cancer	Adlai Nortye Biopharma Co. Ltd.	July 31 2020	Phase 3
NCT02614508	Terminated	Drug: Buparlisib\|Drug: Ibrutinib\|Biological: Ofatumumab	Recurrent Chronic Lymphocytic Leukemia\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Small Lymphocytic Lymphoma	Emory University\|Novartis	January 2016	Phase 1
NCT01613677	Withdrawn	Drug: BKM120	Treatment for Metastatic or Locally Advanced Cervical Cancer	Novartis Pharmaceuticals\|Novartis	November 2015	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Selective PI3K Inhibitors

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
Selective PI3K Inhibitors

TGX-221 : p110β-specific, IC50=5 nM.
Most Potent PI3K Inhibitor

BEZ235 (NVP-BEZ235, Dactolisib) : p110α/γ/δ/β, IC50=4 nM/5 nM/7 nM/75 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

VS-5584 (SB2343) ^New : Potent and selective dual PI3K/mTOR inhibitor for mTOR, PI3Kα/β/δ/γ with IC50 of 3.4 nM and 2.6-21 nM, respectively.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Wortmannin

Wortmannin (KY 12420) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Dactolisib (BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Buparlisib (BKM120)